Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
Des-gamma-carboxy prothrombin (DCP) is measured by an enzyme immunoassay system with the monoclonal antibody MU-3. A novel DCP antibody named 19B7 recognizes a different epitope against the Gla domain of DCP measured by the MU-3 antibody. Therefore, it is possible that DCP variants can be measured with these two antibodies. The aim of this study was to elucidate the usefulness of the DCP ratio as a new prognostic parameter for patients with hepatocellular carcinoma (HCC). One hundred and eighty-three patients with HCC were enrolled in the current study. The DCP ratio was calculated using the formula: DCP ratio = DCP level measured by the MU-3 (mAU/mL) / DCP level measured by the 19B7 (mAU/mL). There was no statistical correlation between DCP level measured by MU-3 antibody and DCP ratio. Clinical stage, tumor type, portal tumor thrombus and DCP were independent factors in the multivariate analysis for survival of 183 patients. In 67 patients with single nodule HCC, clinical stage and DCP ratio were independent factors in the multivariate analysis for survival rate. The most useful prognostic tumor marker was the DCP in the 183 HCC patients and the DCP ratio in single nodule HCC.